Post Profile






'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

(Reuters) - More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday.
read more

share

Related Posts


Preliminary Study: Antibody Therapy Reduces Cancer Stem Cells in Multiple Myeloma

Health : Newswise Medical News

An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of ...

Chinese cell therapy effective in small multiple myeloma trial

Health : Reuters: Health

CHICAGO (Reuters) - A small trial conducted in China found that an experimental therapy using altered cells to recruit the body's immune system to attack cancer can induce remission in most patients with advanced multiple myeloma, a...

Bluebird, Celgene myeloma treatment impresses in tiny study

Health : Reuters: Health

(Reuters) - Most patients who previously were not helped by repeated treatments for multiple myeloma showed strong benefits from a new type of therapy in a small study, and with no worrisome side effects, drugmaker Bluebird Bio Inc ...

Novartis CAR-T therapy leads to durable response in lymphoma study

Health : Reuters: Health

(Reuters) - Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to update...

Roche lymphoma drug drives high remission rate, longer survival: study

Health : Reuters: Health

(Reuters) - An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment ...

Comments


Copyright © 2016 Regator, LLC